Medanta Review
In Indian healthcare, Medanta stands as a symbol of excellence and innovation. Operating under Global Health Limited, it has rapidly evolved into one of the nation’s top multispecialty healthcare providers. With presence in multiple cities and commitment to expanding its reach, Medanta’s journey reflects visionary leadership and healthcare excellence.
Company Name: Global Health Ltd. (operating as Medanta)
Ticker Symbol: MEDANTA
Founded in: Gurgaon, India (2009)
Market Cap: Approximately ₹36,931 crore
Share Prices: ₹1,373.90
P/E Ratio: 82.23
Industry: Hospital & Healthcare Services
Type: Mid Cap
Updated on October 29, 2025
Overview
Medanta is a renowned chain of multi-specialty hospitals known for delivering advanced medical care across India. It is operated by Global Health Ltd., the official name of the parent company, and is often discussed as a stock to buy today among healthcare sector investors. It was founded in 2009 by renowned cardiac surgeon Dr. Naresh Trehan, who serves as the Medanta owner and chairman. The flagship Medanta – The Medicity in Gurugram houses 1,250 beds and provides world-class treatment in cardiology, neurosciences, oncology, transplant surgery, orthopedics, and other specialized fields
Over the years, Medanta has expanded to key cities beyond Gurugram, including Lucknow, Indore, Ranchi, and Patna, with a 550-bed facility in Noida set to open by FY 2025. The hospital group has consistently ranked among the top private hospitals in India and globally. It also leads in medical research through its tissue storage project.
With investments exceeding ₹2,500 crore over 3-4 years, the company will strengthen its metro presence while expanding into emerging healthcare hubs, establishing dominance in India’s premium healthcare sector. Financially, Medanta has demonstrated strong growth—its share price surged over 100% in 2023, and continues to rise steadily in 2024 and 2025, reflecting strong investor confidence and consistent performance.
Timeline Expansion of Medanta
Medanta has pursued an aggressive and strategic expansion across India since its launch. The following timeline summarizes the key milestones and developments in Global Health Ltd. (Medanta) growth:
- 2009: Opened flagship 1,391-bed hospital in Gurugram, establishing Medanta as one of India’s leading providers of specialised medical services.
- 2019–23: Expanded to 950 beds in Lucknow; introduced advanced specialties, becoming the largest private hospital in Uttar Pradesh with strong financial performance.
- 2020–22: Launched 650-bed hospital in Patna; achieved earnings before interest, taxes, depreciation, and amortization (EBITDA) break-even within first year, improving healthcare access in Bihar.
- 2023–25: Established a 750-bed hospital in Pitampura through operations and maintenance partnership and developed a 550-bed facility in Noida nearing phased opening, significantly expanding presence across North Delhi and the NCR region.
- 2024–26: Planned a 500–700 bed Greenfield hospital in Mumbai to enter the western India market, while opening a new 110-bed hospital with 150-bed expansion in Ranchi, doubling capacity and enhancing healthcare delivery in Jharkhand.
Products & Services of Medanta
Medanta offers advanced quaternary care with super-specialty and multi-specialty treatments across over 30 medical specialties, including:
- Cardiology
- Neurology
- Oncology
- Orthopedics
- Digestive and Hepatobiliary Sciences
- Robotic Surgery
- Regenerative Medicine
- Transplant Services
In the future, Global Health Ltd. (Medanta) is positioned to become India’s largest healthcare network, planning to add over 3,000 beds across major cities, including Mumbai, Delhi-NCR, and tier-2 markets like Indore and Guwahati.
Subsidiaries of Medanta
Medanta is expanding across India through strategic subsidiaries and Medanta hospital branches in India that operate hospitals, diagnostics, pharmacies, and specialty care clinics. The key subsidiaries operating in India include:
- Medanta Holdings Pvt Ltd (MHPL): Operates Medanta Lucknow with 410 beds (expandable to 1,000), launched in November 2019. Fully owned by Global Health Ltd.
- Global Health Patliputra Pvt Ltd (GHPPL): Runs Jay Prabha Medanta Super Specialty Hospital in Patna since 2021. Wholly owned subsidiary focusing on Bihar healthcare.
- GHL Pharma & Diagnostic Pvt Ltd: Manages outpatient pharmacies and diagnostic services supporting Medanta’s integrated healthcare model.
- Clinic Subsidiaries: Operates multi-specialty clinics across Gurugram, New Delhi, Patna, and other cities for outpatient services and hospital referrals, managed under various GHL-linked subsidiaries.
Profit & Loss of Medanta
In this Medanta review, we examine how Global Health Ltd. has delivered consistent financial performance, driving positive sentiment around its stock. From FY 2021–22 to FY 2022–23, revenue grew by approximately 24.3%, while profit after tax (PAT) jumped 66.2%, reflecting improved operational margins and patient volumes. In FY 2023–24, revenue rose by another 21.6%, and PAT increased by 46.6% year-over-year. This steady double-digit growth in both top and bottom lines has significantly supported Medanta’s stock rally post-IPO, positioning it as a strong mid-cap player in the healthcare sector.
Is Medanta a Good Investment?
Our Medanta review shows that Global Health Ltd. has attracted attention for its strong fundamentals and potential expansion strategy. Several factors could raise its share price higher. The steady revenue and profit growth signal strong financials, while expansion into Tier 2 cities and the upcoming Noida hospital offer long-term potential. The brand’s strong reputation, high patient occupancy, and leadership in tertiary care also boost investor confidence. Moreover, India’s rising healthcare demand and government focus on private sector participation further support the sector’s momentum.
However, this Medanta review also highlights key risks. Regulatory changes in healthcare pricing, rising competition, and slowdowns in medical tourism or the economy could affect growth. Additionally, healthcare’s capital-intensive nature means project delays or cost overruns may impact profitability. Short-term stock movements may also reflect broader market volatility.
To explore how Global Health Ltd. (Medanta) compares with other top performers in India’s stock market, consider our comprehensive analysis of leading stocks that offer detailed performance insights and comparative data.
Disclaimer
The above content is for informational purposes only and does not constitute investment advice or a stock recommendation. Always conduct your own research or consult with a certified financial advisor before making any investment decisions. Investing in equities carries risk, including the possible loss of capital.
FAQs
Yes, Medanta (Global Health Ltd.) has strong fundamentals with increasing revenue, profitability, and a solid hospital network. It operates in a high-demand sector, has low debt, and continues to expand capacity, making it a promising long-term investment candidate.
Medanta’s quarterly results highlight revenue growth, patient footfall rise, and EBITDA improvements. You can find Global Health Ltd’s current quarterly earnings report on their investor relations webpage or through financial news sources.
Medanta stock has delivered steady returns since its IPO in 2022. It gained traction post-listing due to its profitability and brand value in the healthcare sector. However, past performance may not predict future results, but historical data reflects stable investor confidence.
Medanta earns primarily from in-patient and out-patient services, pharmacy, surgeries, diagnostics, and specialty treatments across its multi-specialty hospitals. Its focus on high-margin tertiary care like cardiac and neuro services boosts revenue sustainability and growth.
While Apollo is larger in scale, Medanta is showing faster revenue growth and margin improvement. Investors see Medanta as a high-potential stock due to its focus on Tier-1 cities and efficient cost control. However, Apollo has broader brand visibility and market presence.
Medanta operates 5 hospitals in India, located in Gurugram, Lucknow, Patna, Indore, and Ranchi, with plans for further expansion.